Alzheimer Disease Clinical Trial
Official title:
Transcranial Magnetic Stimulation (TMS) in Patients With Mild Cognitive Impairment (MCI) and Alzheimer Disease (AD): A Twelve-year Retrospective Observational Study
NCT number | NCT04771845 |
Other study ID # | 20-0812 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2008 |
Est. completion date | May 30, 2020 |
Verified date | February 2021 |
Source | The New York Memory Services |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The investigators reviewed 12 years of clinical use in an outpatient neurology setting of transcranial magnetic stimulation (TMS) in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) to evaluate safety and efficacy of TMS.
Status | Completed |
Enrollment | 73 |
Est. completion date | May 30, 2020 |
Est. primary completion date | May 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients meeting the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) criteria for possible or probable Alzheimer's disease. - Patients meeting the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) criteria for mild cognitive impairment. - Patients must have undergone at least two standardized neurocognitive batteries before and after beginning TMS. - Patients must have received greater than or equal to five (5) TMS sessions in less than one year. Exclusion Criteria: • Patients with dementias from other causes, such as Lewy Body disease. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
The New York Memory Services |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Controlled Oral Word Association Test | Animal score and percentile | 05/01/2008-05/30/2020 | |
Primary | Boston 30-item naming test | spontaneous correct (without cues) | 05/01/2008-05/30/2020 | |
Primary | Boston 30-item naming test | total correct (with cues) | 05/01/2008-05/30/2020 | |
Primary | Wechsler Adult Intelligence Scale III | Digit span | 05/01/2008-05/30/2020 | |
Primary | Wechsler Adult Intelligence Scale III | verbal quotient score and percentile | 05/01/2008-05/30/2020 | |
Primary | Wechsler Adult Intelligence Scale III | performance quotient score and percentile | 05/01/2008-05/30/2020 | |
Primary | Wechsler Adult Intelligence Scale III | object assembly | 05/01/2008-05/30/2020 | |
Primary | Wechsler Memory Scale III | Immediate memory score and percentile | 05/01/2008-05/30/2020 | |
Primary | Wechsler Memory Scale III | Auditory delayed memory score and percentile | 05/01/2008-05/30/2020 | |
Primary | Wechsler Memory Scale III | Visual delayed memory score and percentile | 05/01/2008-05/30/2020 | |
Primary | Buschke Selective Reminding Test, 12 item | Total recall score | 05/01/2008-05/30/2020 | |
Primary | Buschke Selective Reminding Test, 12 item, 15 minute | Delayed recall score | 05/01/2008-05/30/2020 | |
Primary | Rosen Drawing Test | Total score | 05/01/2008-05/30/2020 | |
Primary | Processing speed | Total score and percentile | 05/01/2008-05/30/2020 | |
Primary | Mini-mental status examination | Total score | 05/01/2008-05/30/2020 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |